1 March 2026
Genentech's Fenebrutinib Shows Promise as BTK Inhibitor for MS in Phase III Study
Fenebrutinib reduced relapses by 51% in RMS, consistent with prior studies. Data will be submitted to regulators. Safety profile comparable to teriflunomide; further analysis on fatalities ongoing.
